CompletedPhase 1/2

Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

China30 participantsStarted 2017-12-01

Plain-language summary

The purpose of this proposed research is to evaluate the efficacy and safety of the rapamycin therapy in patients with activated phosphoinositide 3-kinase δ syndrome (APDS).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with activated phosphoinositide 3-kinase δ syndrome
✓. No more than 18 years old

Exclusion criteria

✕. Patients with serious fungous infection
✕. Patients with serious complications
✕. Lack of parental consent

What they're measuring

Frequency of Recurrent Infections

Timeframe: 5 years

Hepatosplenomegaly

Timeframe: 5 years

Lymphocyte subset

Timeframe: 5 years

Trial details

NCT IDNCT03383380

SponsorChildren's Hospital of Fudan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-11-30

View on ClinicalTrials.gov More Activated PI3K-delta Syndrome trials